/

BioCryst Pharmaceuticals, Inc.

BCRX US

BCRX USBioCryst Pharmaceuticals, Inc.

United States Composite

4.06

USD

-0.16

(-3.79%)

-1.18EPS Dil.

-3.44P/E

835.43MMarket Cap

Next Earnings

May 1

Held by Insiders

1.22%

Held by Institutions

88.26%

Short % of Float

14.11%

YTD Yield

-41.12%

3Y Yield

-63.64%

5Y Yield

-44.81%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

LT Borrowings

819

833

811

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

189

190

206

Market Capitalization

1,334

1,344

1,233

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

511

502

496

Cash, Cash Equivalents & STI

411

398

389

Accounts Receivable, Net

Inventories

Total Current Liabilities

150

Payables & Accruals

ST Debt

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

109.66%

187.41%

22.14%

Net Income, GAAP

-24.90%

-20.50%

8.10%

Free Cash Flow

-34.11%

-5.29%

40.49%

Total Cash Common Dividend

- -

Total Equity

-464.02%

-173.18%

-54.58%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

157

2022

271

2023

331

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-0.36

-0.24

-0.33

-0.10

-1.03

2022

-0.40

-0.32

-0.23

-0.38

-1.33

2023

-0.28

-0.40

-0.19

-0.31

-1.18

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. Jon P. Stonehouse
Full Time Employees: 536
Sector: Healthcare
Industry: Biotechnology
Address: 4505 Emperor Boulevard Durham NC United States 27703
CIK: 0000882796
Website: www.biocryst.com
Business: BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Company News

Tipranks
3 days ago
Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Ironwood Pharma (IRWD)
Yahoo
3 days ago
With 80% ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) boasts of strong institutional backing
Yahoo
3 days ago
BioCryst to Report First Quarter 2024 Financial Results on May 6
Yahoo
9 days ago
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
Tipranks
12 days ago
RBC Capital Keeps Their Buy Rating on BioCryst (BCRX)
Tipranks
15 days ago
Optimizing Investment Strategies: A Deep Dive into BioCryst’s Stock Performance
Yahoo
22 days ago
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo
a month ago
BioCryst to Present at Upcoming Investor Conferences
Yahoo
2 months ago
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Company Description

CEO: Mr. Jon P. Stonehouse
Full Time Employees: 536
Sector: Healthcare
Industry: Biotechnology
Address: 4505 Emperor Boulevard Durham NC United States 27703
CIK: 0000882796
Website: www.biocryst.com
Business: BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Company News

Tipranks
3 days ago
Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Ironwood Pharma (IRWD)
Yahoo
3 days ago
With 80% ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) boasts of strong institutional backing
Yahoo
3 days ago
BioCryst to Report First Quarter 2024 Financial Results on May 6
Yahoo
9 days ago
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
Tipranks
12 days ago
RBC Capital Keeps Their Buy Rating on BioCryst (BCRX)
Tipranks
15 days ago
Optimizing Investment Strategies: A Deep Dive into BioCryst’s Stock Performance
Yahoo
22 days ago
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo
a month ago
BioCryst to Present at Upcoming Investor Conferences
Yahoo
2 months ago
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)